As mentioned above, the exhaustion of CD8+ T cells in MDS is associated with the activation of the TIM3 pathway, which provides a rationale for the application of TIM3 inhibitors in higher-risk MDS patients [60,61,63]. The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.